Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06847724 · ClinicalTrials.gov registry record · Phase 3
Comparative PK, PD, Efficacy, and Safety Assessment of the Proposed Ocrelizumab Biosimilar CYB704 and Ocrevus in Participants With Relapsing Multiple Sclerosis
A Phase 3 study of Relapsing Multiple Sclerosis, sponsored by Sandoz.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 175
- Enrollment target
- 20
- Study locations
NCT06847724 is a Phase 3 study of Relapsing Multiple Sclerosis that is actively recruiting participants, run by Sandoz. The registered enrollment target is 175 participants, below the 2,162-participant average among 23 other Relapsing Multiple Sclerosis trials with a reported enrollment target (92% lower). The trial reports 20 study locations across 2 states.
The verdict
NCT06847724, a Phase 3 study of Relapsing Multiple Sclerosis, is actively recruiting participants, sponsored by Sandoz.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 175 participants
- Enrollment target
- 20
- Study locations
Study Summary
The goal of this clinical trial is to learn if drug CYB704, a proposed biosimilar to Ocrevus, works to treat multiple sclerosis in the same way as the reference product Ocrevus(R). The main questions it aims to answer are: * Is CYB704 distributed in the body in the same way as the reference product (demonstration of pharmacokinetic (PK) similarity)? * Does have CYB704 the same treatment effect and side effects as the reference product? Researchers will compare CYB704 to a Ocrevus (Ocrevus-US and Ocrevus-EU). Participants will: * Take drug CYB704 or Ocrevus (Ocrevus-US and Ocrevus-EU) * Visit the clinic for at least 15 treatment visits, checkups and tests * Will undergo regular magnetic resonance imaging (MRI) examinations
Conditions Studied
Interventions
- BIOLOGICAL CYB704
- BIOLOGICAL Ocrevus-EU
- BIOLOGICAL Ocrevus-US
Study Locations (20)
Other
- Sandoz Investigational Site - Banja Luka
- Sandoz Investigational Site - Bihać
- Sandoz Investigational Site 2 - Sarajevo
- Sandoz Investigational Site - Sarajevo
- Sandoz Investigational Site - Pleven
- Sandoz Investigational Site 2 - Plovdiv
- Sandoz Investigational Site - Plovdiv
- Sandoz Investigational Site 2 - Sofia
- Sandoz Investigational Site 3 - Sofia
- Sandoz Investigational Site 4 - Sofia
- Sandoz Investigational Site 5 - Sofia
- Sandoz Investigational Site - Sofia
- Sandoz Investigational Site - Varaždin
- Sandoz Investigational Site - Zagreb
- Sandoz Investigational Site - Rustavi
- Sandoz Investigational Site 2 - Tbilisi
- Sandoz Investigational Site 3 - Tbilisi
- Sandoz Investigational Site 4 - Tbilisi
Florida
- Sandoz Investigational Site - Maitland
- Sandoz Investigational Site - Ormond Beach
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 175 participants |
| Start Date | 2025-06-10 |
| Est. Completion | 2029-10-14 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06847724
The ClinicalTrials.gov registry entry for NCT06847724 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 175 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,162-participant average among 23 other Relapsing Multiple Sclerosis trials with a reported enrollment target (92% lower). The listed sponsor is Sandoz, which has 29 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Relapsing Multiple Sclerosis appearing as the primary indexed condition, and to 3 interventions - of which CYB704 is the first listed.
NCT06847724 reports 20 study locations spanning 2 distinct geographic areas - top geographies include Other, Florida.
Frequently Asked Questions
What is clinical trial NCT06847724 about?
NCT06847724 is a clinical study titled "Comparative PK, PD, Efficacy, and Safety Assessment of the Proposed Ocrelizumab Biosimilar CYB704 and Ocrevus in Participants With Relapsing Multiple Sclerosis". The goal of this clinical trial is to learn if drug CYB704, a proposed biosimilar to Ocrevus, works to treat multiple sclerosis in the same way as the reference product Ocrevus(R). The main questions it aims to answer are: * Is CYB704 distributed in the body in the same way as the reference produc...
What is the current status of trial NCT06847724?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 175 participants. The study started on 2025-06-10. Estimated completion is 2029-10-14.
What conditions does trial NCT06847724 study?
This clinical trial studies the following conditions: Relapsing Multiple Sclerosis.
What interventions are being tested in trial NCT06847724?
The interventions under investigation include: CYB704 (BIOLOGICAL), Ocrevus-EU (BIOLOGICAL), Ocrevus-US (BIOLOGICAL).
Who is sponsoring clinical trial NCT06847724?
This trial is sponsored by Sandoz, which has 29 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06847724 being conducted?
This trial has 20 study locations across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Relapsing Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab
RECRUITING · Phase 3
-
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
RECRUITING · Phase 3
-
Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)
RECRUITING · Phase 3
-
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)
ACTIVE NOT RECRUITING · Phase 3
-
Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.